Albert B. Deisseroth
33Patents
5h-index
12Co-inventors
66Inventor score
Filing activity: Jul 29, 1993 → Apr 22, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5417978A | Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use | Chemistry; Metallurgy | 123 | Expired |
| US8119117B2 | Adenoviral expression vector comprising a CD40L fusion protein adapted to elicit cellular immunity | Chemistry; Metallurgy | 23 | Active |
| US8828957B2 | Methods for generating immunity to antigen | Chemistry; Metallurgy | 6 | Active |
| US8299229B2 | Mucin antigen vaccine | Chemistry; Metallurgy | 6 | Expired |
| US8236295B1 | Composition comprising an adenoviral expression vector comprising a CD40L fusion protein for generating immune responses | Chemistry; Metallurgy | 5 | Active |
| US8501707B2 | Mucin antigen vaccine | Chemistry; Metallurgy | 4 | Active |
| US9533036B2 | Methods for generating immune responses to influenza antigens with a secretable CD40L fusion protein | Chemistry; Metallurgy | 4 | Active |
| US10046041B2 | Methods and compositions for suppressing virulence of methicillin resistant Staphylococcus aureus | Chemistry; Metallurgy | 2 | Active |
| US8540979B2 | Methods of generating immune responses with compositions comprising an adenoviral expression vector comprising a CD40L fusion protein | Chemistry; Metallurgy | 2 | Active |
| US8742087B2 | Mucin antigen vaccine | Chemistry; Metallurgy | 2 | Active |
| US9353167B2 | Methods for generating immunity to antigen | Chemistry; Metallurgy | 2 | Active |
| US10383932B2 | Vaccine directed to induction of immune response to protein and glycolipid antigens of bacterial cells through interaction of CD4OL/CD40 receptor axis with complex of glycolipid/CD1d receptor in NKT cells and in dendritic cells | Chemistry; Metallurgy | 1 | Active |
| US7304092B1 | Compounds and methods for treating tumors, cancer and hyperproliferative diseases | Chemistry; Metallurgy | 1 | Expired |
| US9526774B1 | Methods and compositions for suppressing virulence of methicillin resistant Staphylococcus aureus | Chemistry; Metallurgy | 1 | Active |
| US9458221B2 | Adenoviral expression vector encoding a CD40L fusion protein | Chemistry; Metallurgy | 1 | Active |
| US9402920B2 | Mucin antigen vaccine | Chemistry; Metallurgy | 1 | Active |
| US9642901B1 | TAA/CD40L vaccine for malaria | Emerging Cross-Sectional Technologies | 1 | Active |
| US9757438B2 | Mucin antigen vaccine | Chemistry; Metallurgy | 1 | Active |
| US10149899B1 | Composition and method against C-difficile | Chemistry; Metallurgy | 0 | Active |
| US12427191B1 | SARS-CoV-2 fusion protein vaccine/regimen | Chemistry; Metallurgy | 0 | Active |
| US10835589B2 | Vaccine directed to induction of immune response to protein and glycolipid antigens of bacterial cells through interaction of CD40L/CD40 receptor axis with complex of glycolipid/CD1d receptor in NKT cells and in dendritic cells | Chemistry; Metallurgy | 0 | Active |
| US10130667B1 | TAA/ecdCD40L oncolytic virus | Chemistry; Metallurgy | 0 | Active |
| US10166284B1 | Vaccines for herpes simplex virus 1 and 2 | Chemistry; Metallurgy | 0 | Active |
| US10293040B1 | Pharmaceutical compositions and methods of blocking Bacillus anthracis | Chemistry; Metallurgy | 0 | Active |
| US11077183B2 | CD40 ligand fusion protein vaccine | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.